BioAIM in Action: Integrating Wet and Digital Labs to Accelerate Biologics Discovery at Sanofi
In this webinar, discover how Sanofi is advancing AI in biopharma research and development by building an integrated wet and digital lab environment to accelerate large‑molecule research. Yves Fomekong Nanfack, Executive Director and Head of End‑to‑End AI Foundation at Sanofi, shares how the company leverages Genedata Biologics to harmonize global R&D operations, strengthen AI data governance, and ensure FAIR data and AI data integrity across scientific workflows.
A central focus is the BioAIM program—Sanofi’s next‑generation biologics platform designed to embed AI in scientific discovery and AI in scientific research throughout the discovery pipeline. You’ll gain insights into how digital transformation, structured data integration, and AI/ML‑driven drug discovery strategies are enabling a scalable, future‑ready R&D ecosystem.
Learn how Sanofi uses Genedata to:
- Integrate wet and digital labs by unifying experimental and computational workflows, enabling seamless collaboration across R&D functions.
- Accelerate biologics discovery through AI/ML‑driven design, virtual screening, in silico‑first strategies, and modern AI drug discovery approaches.
- Modernize and harmonize global R&D operations by standardizing data capture, workflows, and systems across sites.
- Support the BioAIM program—a next‑generation digital biologics platform—by providing the data infrastructure required for AI‑guided discovery.
- Build a four‑pillar digital ecosystem encompassing Digital Foundations, Data Foundations, AI Capabilities, and Front‑End UX, supported by scalable AI cloud solutions.
- Ensure robust data governance with structured registration, traceability, and audit‑ready documentation aligned with ALCOA+ principles.
- Enable AI/ML model development through high‑quality, metadata‑rich datasets and strong data governance for AI.
- Reduce development timelines and improve molecule quality by integrating automation, analytics, and predictive modeling.
- Empower scientists with intuitive digital tools that enhance productivity and support next‑generation biopharma AI workflows.
Who Should Watch:
- R&D Scientists and Innovation Leaders: Gain practical insights into streamlining biologics discovery, reducing optimization cycles, and accelerating timelines through digital platforms and AI.
- Data Scientists, AI/ML Specialists, and Bioinformatics Teams: Learn how to access and leverage high-quality, metadata-rich datasets to build, deploy, and scale impactful AI/ML models in biologics research.
- IT, Informatics, and Scientific Software Developers: Explore strategies for integrating legacy systems, supporting scalable infrastructure, and developing user-friendly tools that enhance scientific workflows.
- Innovation Managers and Program Leads: See how AI and digital tools can accelerate timelines and deliver measurable R&D impact.
- Regulatory, Quality, and Data Governance Experts: Understand how structured data capture, traceability, and audit-ready documentation support compliance and IP protection, and data stewardship.
- Biotech Executives, Program Leads, and Collaborators: Evaluate the strategic value of digital transformation in biologics R&D and explore collaboration models that drive innovation and measurable impact.
Also Watch:
